103 related articles for article (PubMed ID: 17602576)
1. The ester group: how hydrofluoroalkane-philic is it?
Peguin RP; Wu L; da Rocha SR
Langmuir; 2007 Jul; 23(16):8291-4. PubMed ID: 17602576
[TBL] [Abstract][Full Text] [Related]
2. Understanding solvation in hydrofluoroalkanes: ab initio calculations and chemical force microscopy.
Wu L; Peguin RP; da Rocha SR
J Phys Chem B; 2007 Jul; 111(28):8096-104. PubMed ID: 17580855
[TBL] [Abstract][Full Text] [Related]
3. Characterization of suspension-based metered dose inhaler formulations composed of spray-dried budesonide microcrystals dispersed in HFA-134a.
Tarara TE; Hartman MS; Gill H; Kennedy AA; Weers JG
Pharm Res; 2004 Sep; 21(9):1607-14. PubMed ID: 15497686
[TBL] [Abstract][Full Text] [Related]
4. Novel propellant-driven inhalation formulations: engineering polar drug particles with surface-trapped hydrofluoroalkane-philes.
Wu L; Al-Haydari M; da Rocha SR
Eur J Pharm Sci; 2008 Feb; 33(2):146-58. PubMed ID: 18083015
[TBL] [Abstract][Full Text] [Related]
5. Reverse aqueous emulsions and microemulsions in HFA227 propellant stabilized by non-ionic ethoxylated amphiphiles.
Chokshi U; Selvam P; Porcar L; da Rocha SR
Int J Pharm; 2009 Mar; 369(1-2):176-84. PubMed ID: 19028557
[TBL] [Abstract][Full Text] [Related]
6. Biocompatible and biodegradable copolymer stabilizers for hydrofluoroalkane dispersions: a colloidal probe microscopy investigation.
Wu L; da Rocha SR
Langmuir; 2007 Nov; 23(24):12104-10. PubMed ID: 17958454
[TBL] [Abstract][Full Text] [Related]
7. The potential for the noninvasive delivery of polymeric nanocarriers using propellant-based inhalers in the treatment of Chlamydial respiratory infections.
Bharatwaj B; Wu L; Whittum-Hudson JA; da Rocha SR
Biomaterials; 2010 Oct; 31(28):7376-85. PubMed ID: 20615546
[TBL] [Abstract][Full Text] [Related]
8. The chlorofluorocarbon to hydrofluoroalkane transition: the effect on pressurized metered dose inhaler suspension stability.
Brindley A
J Allergy Clin Immunol; 1999 Dec; 104(6):S221-6. PubMed ID: 10588978
[TBL] [Abstract][Full Text] [Related]
9. The effects of polyvinyl alcohol on the in vitro stability and delivery of spray-dried protein particles from surfactant-free HFA 134a-based pressurised metered dose inhalers.
Liao YH; Brown MB; Jones SA; Nazir T; Martin GP
Int J Pharm; 2005 Nov; 304(1-2):29-39. PubMed ID: 16181753
[TBL] [Abstract][Full Text] [Related]
10. Solvent-solute interactions in hydrofluoroalkane propellants.
Peguin RP; da Rocha SR
J Phys Chem B; 2008 Jul; 112(27):8084-94. PubMed ID: 18598010
[TBL] [Abstract][Full Text] [Related]
11. Solvation in hydrofluoroalkanes: How can ethanol help?
Conti DS; Grashik J; Yang L; Wu L; da Rocha SR
J Pharm Pharmacol; 2012 Sep; 64(9):1236-44. PubMed ID: 22881436
[TBL] [Abstract][Full Text] [Related]
12. Reverse aqueous microemulsions in hydrofluoroalkane propellants and their aerosol characteristics.
Selvam P; Bharatwaj B; Porcar L; da Rocha SR
Int J Pharm; 2012 Jan; 422(1-2):428-35. PubMed ID: 22044539
[TBL] [Abstract][Full Text] [Related]
13. The influence of initial atomized droplet size on residual particle size from pressurized metered dose inhalers.
Sheth P; Stein SW; Myrdal PB
Int J Pharm; 2013 Oct; 455(1-2):57-65. PubMed ID: 23911912
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers.
Hochrainer D; Hölz H; Kreher C; Scaffidi L; Spallek M; Wachtel H
J Aerosol Med; 2005; 18(3):273-82. PubMed ID: 16181002
[TBL] [Abstract][Full Text] [Related]
15. Isothermal calorimetry: a predictive tool to model drug-propellant interactions in pressurized metered dose systems.
Ooi J; Gaisford S; Boyd BJ; Young PM; Traini D
Int J Pharm; 2014 Jan; 461(1-2):301-9. PubMed ID: 24325938
[TBL] [Abstract][Full Text] [Related]
16. Clinical comparability between the CFC and HFA budesonide pressurised metered-dose inhalers in paediatric patients with asthma: a randomised controlled trial.
Escribano A; Tutuncu A; Löhr I; Carlholm M; Polanowski T
Curr Med Res Opin; 2006 Jun; 22(6):1085-92. PubMed ID: 16846541
[TBL] [Abstract][Full Text] [Related]
17. HPFP, a model propellant for pMDIs.
Rogueda PG
Drug Dev Ind Pharm; 2003 Jan; 29(1):39-49. PubMed ID: 12602491
[TBL] [Abstract][Full Text] [Related]
18. The effect of ethanol on the formation and physico-chemical properties of particles generated from budesonide solution-based pressurized metered-dose inhalers.
Zhu B; Traini D; Chan HK; Young PM
Drug Dev Ind Pharm; 2013 Nov; 39(11):1625-37. PubMed ID: 24087854
[TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind, double-dummy, single-dose, efficacy crossover trial comparing formoterol-HFA (pMDI) versus formoterol-DPI (Aerolizer) and placebo (pMDI or Aerolizer) in asthmatic patients.
Bousquet J; Huchon G; Leclerc V; Vicaut E; Lefrançois G
Respiration; 2005; 72 Suppl 1():6-12. PubMed ID: 15915007
[TBL] [Abstract][Full Text] [Related]
20. An investigation of the solubility of various compounds in the hydrofluoroalkane propellants and possible model liquid propellants.
Dickinson PA; Seville PC; McHale H; Perkins NC; Taylor G
J Aerosol Med; 2000; 13(3):179-86. PubMed ID: 11066021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
